AFT notes Maxigesic(R) sales estimates in new market research

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 23 January 2020

AFT notes Maxigesic
®
sales estimates in new market
research
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) notes the publication of new market
research that estimates the potential for AFT’s patented medicine Maxigesic in
managing postoperative pain in the US, Japan and the top 5 European Union
countries [France, Germany, Italy, Spain and UK].
The independent research, entitled ‘Postoperative Pain Market Insights, Epidemiology
and Market Forecast—2028’
1
, estimates the Maxigesic platform has the potential to
generate sales of US$441.9 million in these markets by 2028.
The research, by life science consulting and market research firm Delveinsight
https://www.delveinsight.com
), also estimates the market for postoperative pain relief
will grow at a compound annual growth rate of 10.26% from US$1.1 billion in 2019 to
reach US$2.6 billion in 2028.
AFT Pharmaceuticals Managing Director Hartley Atkinson said Delveinsight’s forecasts
for Maxigesic were prepared independently of AFT and that AFT was unaware that
the research was being undertaken, and the company expresses no view on the
accuracy of the research nor its conclusions.
“We note that the conclusions of the report are subject to a number of assumptions
including one that AFT will obtain regulatory approval of the intravenous formulation,
Maxigesic IV, in 2021 in the two largest markets identified in the study, the US and
Japan. However, it is positive that the market is seen to more than double over this
time period with the anticipated increase in new non-opioid analgesic medications
for treatment of post-operative pain.
“AFT is seeking regulatory approvals for Maxigesic in Europe, Japan and the US.
However, there can be no certainty of achieving these goals within the timeframe
specified in the DelveInsight report.
“Moreover, even if the company does obtain the necessary regulatory approvals
within the specified timeframe, there is no certainty that licensees in these markets will
make the sales estimated in the report, AFT has to date licensed Maxigesic IV in over
70 countries including recently Canada, Indonesia and Pakistan. However, it is positive

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

that an independent party sees the market category as growing and that Maxigesic
is well placed to compete with new products in the category” Dr Atkinson said.
AFT has already received regulatory approval for the tablet form of the Maxigesic
medication in 44 countries including all members of the European Union and the UK.
It has also obtained regulatory approval for the intravenous form of Maxigesic in
Australia and New Zealand to date with a significant number of new registrations
presently underway and to be filed during this calendar year.
“AFT will be making no further comment on the DelveInsight report,” Dr Atkinson said.
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO
Notes to editors:
Maxigesic IV is a patented, fixed ratio of ibuprofen (as sodium dihydrate 300 mg) for
anti-inflammation management and paracetamol (1000 mg) for pain management.
Its tablet form is licensed in more than 125 jurisdictions worldwide, registered in 44
jurisdictions and sold in 24 under a variety of different brands
2
. AFT is also licensing and
seeking regulatory approval for other dose forms of the medication including
Maxigesic IV.

1
Postoperative Pain Market Insights, Epidemiology and Market Forecast—2028.
Delveinsight.
2
As at 30 September 2019.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.